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AbstrACt
Objectives Stress urinary incontinence (SUI) and stress- 
predominant mixed urinary incontinence (MUI) are common 
conditions that can have a negative impact on the quality of 
life of patients and serious cost implications for healthcare 
providers. The objective of this study was to assess the 
cost- effectiveness of nine different surgical interventions for 
treatment of SUI and stress- predominant MUI from a National 
Health Service and personal social services perspective in 
the UK.
Methods A Markov microsimulation model was developed 
to compare the costs and effectiveness of nine surgical 
interventions. The model was informed by undertaking a 
systematic review of clinical effectiveness and network 
meta- analysis. The main clinical parameters in the model 
were the cure and incidence rates of complications after 
different interventions. The outcomes from the model were 
expressed in terms of cost per quality- adjusted life- years 
(QALYs) gained. In addition, expected value of perfect 
information (EVPI) analyses were conducted to quantify the 
main uncertainties facing decision- makers.
results The base- case results suggest that retropubic mid- 
urethral sling (retro- MUS) is the most cost- effective surgical 
intervention over a 10- year and lifetime time horizon. The 
probabilistic results show that retro- MUS and traditional sling 
are the interventions with the highest probability of being 
cost- effective across all willingness- to- pay thresholds over a 
lifetime time horizon. The value of information analysis results 
suggest that the largest value appears to be in removing 
uncertainty around the incidence rates of complications, the 
relative treatment effectiveness and health utility values.
Conclusions Although retro- MUS appears, at this stage, 
to be a cost- effective intervention, research is needed on 
possible long- term complications of all surgical treatments 
to provide reassurance of safety, or earlier warning of 
unanticipated adverse effects. The value of information 
analysis supports the need, as a first step, for further 
research to improve our knowledge of the actual incidence of 
complications.
IntrOduCtIOn
Stress urinary incontinence (SUI) in women 
is a disabling and common condition which 
reduces quality of life and causes signifi-
cant stress and concern among individual 
patients.1 2 Commonly defined as the ‘invol-
untary leakage of urine’ due to activities 
such as coughing, sneezing or exercising, the 
prevalence of SUI varies (20% to 50%) but 
is greater in women who have had children 
and in older women.3 4 Associated conditions 
include urge urinary incontinence (UUI), 
which is characterised by a sudden and 
uncontrollable need to urinate (ie, urgency), 
and mixed urinary incontinence (MUI) 
which refers to a combination of the symp-
toms associated with SUI and UUI.2 Where 
the symptoms of SUI dominate those of UUI 
in a patient with MUI, stress- predominant 
MUI is said to exist.
In addition to the emotional impact that 
SUI can have on patients, there are serious 
cost implications associated with the condi-
tion, both for the healthcare provider and 
strengths and limitations of this study
 ► An economic model has been developed to consider 
the relative cost- effectiveness of nine different sur-
gical interventions for stress urinary incontinence 
and stress- predominant mixed urinary incontinence 
in a UK setting.
 ► The model has been informed and populated based 
on a comprehensive systematic review and network 
meta- analysis of the clinical effectiveness of surgi-
cal interventions.
 ► Uncertainty in the model results has been explored 
through a probabilistic sensitivity analysis, and val-
ue of information analysis, to consider the value of 
future research.
 ► Due to limited long- term data on effectiveness, 
short- term data were extrapolated over a longer- 
term time horizon.
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the individual patient.5 Among the previous studies to 
have investigated the economic burden of the condition, 
one published study based on data from three European 
countries suggested that the total cost of SUI is approxi-
mately £818 million in the UK,2 while another suggested a 
healthcare cost to the UK National Health Service (NHS) 
of £117 million per year (SUI only).5 In addition to the 
health service costs, patients may incur out- of- pocket 
expenses due to the need to purchase consumables and 
services not available through their healthcare provider.5
Conservative treatment with physiotherapy to deliver 
pelvic floor muscle exercises and bladder training is the 
first- line of treatment for patients with SUI. However, 
when this fails, or when insufficient relief from symptoms 
is achieved, surgery is the recommended treatment.6 
The aim of surgery is to support or partially obstruct the 
bladder neck and/or urethra, thus preventing the leakage 
of urine on exertion.7 Surgical techniques have evolved 
over time, moving most recently to more minimally inva-
sive techniques, such as mid- urethral slings (MUS) where 
a synthetic mesh or tape is placed under the urethra and 
secured using a number of different methods.8 However, 
it is unclear if these newly available treatments such as 
retropubic mid- urethral sling (retro- MUS), single inci-
sion sling and injectable bulking agents really result in 
equivalent or better cost and health outcomes than older 
operations that were previously available (such as ante-
rior vaginal repair or colposuspension).
The wide range of surgical operations available, the 
different techniques used to perform these operations 
and the lack of a consensus among surgeons regarding 
which approach to use, make it challenging to establish 
which procedure should be used to treat SUI or stress- 
predominant MUI. Health economic techniques have 
become increasingly important as a tool to help inform 
decisions between treatments and interventions. They 
allow for the consideration of all relevant costs (from 
the specified perspective) and clinical outcomes associ-
ated with the treatments being compared. Findings can 
then be used to make a decision on how best to allocate 
resources in the most cost- effective way. This study was 
conducted as part of a larger project to evaluate the cost- 
effectiveness of retro- MUS versus eight different compar-
ator surgical interventions for the treatment of women 
with SUI or stress- predominant MUI.9
MethOds
study design
A Markov microsimulation (MM) model was developed 
to assess cost- effectiveness. The model was informed by a 
review of published economic evaluations, and the find-
ings of a systematic review of clinical effectiveness and 
network meta- analyses (including 120 trials) conducted 
as part of the larger project to estimate the relative effec-
tiveness of nine different surgical treatments.9 Retro- MUS 
was chosen as the intervention against which all other 
surgical interventions would be compared, due to the fact 
that it is the most common type of surgery and it is widely 
regarded as standard practice.10 The eight comparators 
were: (1) anterior vaginal repair or anterior colporrhaphy 
(anterior repair), (2) bladder neck needle suspensions 
(bladder neck needle), (3) open abdominal retropubic 
colposuspension (open- colpo), (4) laparoscopic retro-
pubic colposuspension (lap- colpo), (5) traditional subu-
rethral retropubic sling procedures (trad- sling), (6) 
transobturator mid- urethral sling (transob- MUS), (7) 
single incision sling procedures (single incision sling) 
and (8) periurethral injection bulking agents (injectable 
agents).
Health outcomes from the model were expressed in 
terms of quality- adjusted life- years (QALYs) and costs in 
2018/2019 GBP (£). The costs were estimated from the 
NHS and personal social services perspective. Both costs 
and QALYs were evaluated over 1- year, 10- year and life-
time time horizons and discounted using a 3.5% annual 
discount rate.11 The expected cost and QALYs for each 
of the strategies were compared using incremental cost- 
effectiveness ratios (ICERs) where appropriate.
target population
The model was based on a hypothetical group of women 
(45 to 55 years) with SUI or stress- predominant MUI, 
undergoing surgical intervention for their condition.
Model structure
The model structure is presented in figure 1. Treatment 
history for both SUI/stress- predominant MUI and UUI 
was recorded for each modelled woman and used to define 
the patient transitions to different health states and treat-
ment types. The model assumes that patients can receive 
a maximum of three surgical treatments for treatment of 
SUI/stress- predominant MUI, which includes the initial 
surgery plus two subsequent re- treatments. MUS can be 
offered after the failure of all surgery types, and therefore 
re- treatment was always assumed to be either retro- MUS 
(55%) or transob- MUS (45%). If all three surgeries fail, 
patients have to manage their symptoms using contain-
ment products. The model allows for individuals to elect 
to use containment products at any point after the initial 
treatment has failed. Patients with stress- predominant 
MUI who still have UUI after SUI is cured, or those who 
develop UUI due to a surgery, that is, as a complication 
following the procedure, will receive three lines of treat-
ment based on clinical guidelines including first- line 
(bladder training), second- line (medication) and third- 
line treatment (botulinum toxin A). The model was 
developed in TreeAge Pro package (TreeAge Software, 
Inc, Williamstown, Massachusetts, USA).12
Model inputs
Effectiveness of surgical treatments
The relative effectiveness of surgical treatments, in terms 
of subjective cure rates, were based on the results of a 
network meta- analysis.9 Table 1 describes the mean and 
median ORs for different surgical treatments versus 
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Figure 1 Markov model structure. SUI, stress urinary incontinence.
Table 1 ORs of cure rates for surgical interventions compared with retro- MUS
Treatment Mean Median
Lower bound of 
95% Crl
Upper bound of 
95% Crl
Transob- MUS versus retro- MUS 0.742 0.738 0.588 0.923
Open- colpo versus retro- MUS 0.874 0.853 0.544 1.325
Lap- colpo versus retro- MUS 0.605 0.58 0.315 1.046
Trad- sling versus retro- MUS 1.106 1.061 0.623 1.846
Single incision versus retro- MUS 0.511 0.504 0.36 0.699
Bladder neck needle versus retro- MUS 0.368 0.34 0.154 0.745
Anterior repair versus retro- MUS 0.235 0.22 0.105 0.452
anterior repair, anterior vaginal repair (anterior colporrhaphy); bladder neck needle, bladder neck needle suspensions; Crl, credible interval; 
lap- colpo, laparoscopic retropubic colposuspension; MUS, mid- urethral sling; open- colpo, open abdominal retropubic colposuspension; 
retro- MUS, retropubic mid- urethral sling; single incision, single incision sling procedures (‘mini- slings’); trad- sling, traditional suburethral 
retropubic sling procedures; transob- MUS, transobturator mid- urethral sling.
retro- MUS. The absolute cure rates were calculated in 
the model by combining the information on relative 
cure rates described in Table 1 with the absolute cure 
rates for retro- MUS, presented in table 2. The long- term 
recurrence rates after retro- MUS were estimated using 
parametric survival models. Scale and shape parameters 
were estimated for a Weibull hazard function using the 
reported cure rates at 1 year and 5 years (online supple-
mentary table S1, online supplementary figure S1, online 
supplementary table S2 and online supplementary figure 
S2, respectively). In the base- case analysis, it was assumed 
that 75% of women whose first treatment was not 
successful would seek re- treatment and 30% of women 
whose first re- treatment failed would seek a second 
re- treatment.13 Due to data limitations, it was not possible 
to estimate the success rates of re- treatment following 
failure of prior surgery. Therefore, in the model it was 
assumed that subsequent surgeries (retro- MUS or tran-
sob- MUS) were 90% as effective as when administered as 
a primary surgery.
Complication and mortality rates after surgical treatments
The model incorporated only severe complications/
adverse events that are most important in terms of their 
effect on patient’s quality of life, cost and duration 
of impact. To estimate complication incidence rates, 
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Table 2 Estimation of absolute cure rates after retro- MUS 
in different time points - results from meta- analysis
Time Median 95% Crl
Number 
of studies
Number of 
participants
6 months 0.776 (0.175 to 0.983) 17 908
12 months 0.841 (0.214 to 0.990) 44 2882
24 months 0.784 (0.454 to 0.941) 6 315
36 months 0.341 (0.001 to 0.995) 5 205
60 months 0.329 (0.005 to 0.979) 3 377
Crl, credible interval; retro- MUS, retropubic mid- urethral sling.
random- effects meta- analysis models were fitted to data 
on complication rates from the randomised controlled 
trials identified within the wider systematic review.14 All 
of the complications included in the model, and esti-
mated incidence rates, are presented in online supple-
mentary table S3. In the model, these complication rates 
were defined as distributions (beta distribution). Where 
evidence for particular adverse events associated with 
specific procedures were not identified, it was assumed 
that this complication would not occur. Age- specific all- 
cause mortality rates were derived from general popula-
tion mortality statistics reported in national life tables.15 
The effectiveness of the three lines of treatment for 
UUI were informed by the results from previous meta- 
analyses.6 16
Resource use and unit costs
Surgeries for SUI vary in terms of the complexity of the 
procedure and the setting in which surgery is conducted. 
For patients undergoing anterior repair, bladder neck 
needle, open- colpo, lap- colpo and trad- sling, surgery 
would typically be conducted in an inpatient setting. 
Patients undergoing retro- MUS, transob- MUS, single 
incision sling and injectable agents would typically be 
treated in a day- case setting. In addition to the cost of 
individual surgeries, costs associated with complementary 
tests, treatments and consultations that would typically 
be carried out in advance of, and following, each surgery 
were also considered. Unit costs were derived from UK 
NHS reference costs,17 Personal Social Services Research 
Unit18 and British National Formulary19 for medication. 
The price year of the analysis was 2018/2019. Where 
sources used to derive costs were from prior to 2019, 
these costs were inflated to a 2019 price year. All costs are 
reported in online supplementary table S4.
Health utility
The baseline health utility value for pre- treatment SUI 
was derived from a previous UK- based economic evalu-
ation comparing two types of surgical intervention for 
this condition.20 The utility value for a successful treat-
ment was derived from a UK- based study exploring health 
outcomes in women with urinary incontinence.21 Utility 
decrements associated with each complication included 
in the model were obtained from previous studies22 23 
(online supplementary table S5).
Patient and public involvement
As part of the larger project,9 patient and public involve-
ment (PPI) was included to understand patient’s thoughts 
and feelings regarding their condition and treatment 
and to help add context to the review and meta- analysis 
of clinical effectiveness. However, no additional PPI was 
sought for this modelling work.
Analysis and sensitivity analyses
Both deterministic and probabilistic sensitivity anal-
yses (PSA) were used to explore parameter and other 
forms of uncertainty surrounding the estimates of cost- 
effectiveness. Deterministic sensitivity analyses including; 
applying higher incidence rates of mesh complications, 
longer durations of persistent pain complication, higher 
incidence rates for persistent pain complication post 
MUS procedures and applying different values for short- 
term and long- term cure rates after retropubic MUS 
were performed to determine the impact of changing 
key parameters and assumptions on the model results. 
The PSA was run with 1000 simulations for each patient, 
and cost- effectiveness acceptability curves (CEACs) were 
produced in order to identify the probability of the 
different surgeries being cost- effective across a range 
of willingness- to- pay (WTP) thresholds. The economic 
model was used to quantify the main uncertainties facing 
decision- makers and to help inform decisions about the 
direction of future research. This was explored through 
value of information (VOI) analysis methods: expected 
value of perfect information (EVPI) and expected value 
of partial perfect information (EVPPI) analysis. In total, it 
was assumed that in the UK 15 000 surgical treatments are 
conducted annually for the treatment of SUI.
results
base-case analysis
The base- case analysis results are presented in table 3, 
and in the form of a CEAC (lifetime time horizon) in 
figure 2. The table reports strategies from the least to the 
most costly. Over a lifetime time horizon, retro- MUS is, 
on average, the least costly (£8666) and the second most 
effective (24.005 QALYs) surgical treatment. Trad- sling 
is more costly (+ £405) but also more effective (+0.009) 
than retro- MUS over the lifetime; however, it is not cost- 
effective, based on the National Institute for Health and 
Care Excellence WTP threshold, with an ICER of £45 340. 
All other surgical treatments are dominated, as they 
are more costly and less effective than retro- MUS. Both 
retro- MUS and trad- sling have similarly high probabilities 
of being cost- effective at £20 000 (51% and 43%, respec-
tively) and £30 000 (48% and 45%, respectively) WTP 
thresholds over a lifetime time horizon. Over a 10- year 
time horizon, retro- MUS is the dominant strategy with 
a greater than 90% probability of being cost- effective 
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Table 3 Results of the probabilistic analysis at 1 year, 10 years and lifetime time horizons
Time 
horizon Strategy Cost (£)
Incremental 
cost (£) QALY
Incremental 
QALY
ICER (£) 
(∆cost/∆QALY)
Probability of being 
cost- effective at 
different threshold (%)
£20 000 £30 000
1 year Single incision sling 1844 0.764 100% 100%
Transob- MUS 2470 626 0.752 −0.012 Dominated 0% 0%
Retro- MUS 2490 646 0.752 −0.012 Dominated 0% 0%
Bladder neck needle 2682 838 0.757 −0.006 Dominated 0% 0%
Injectable agents 2705 861 0.742 −0.021 Dominated 0% 0%
Trad- sling 2941 1097 0.725 −0.038 Dominated 0% 0%
Anterior repair 2955 1111 0.766 0.002 522 756 0% 0%
Open- colpo 4847 1891 0.775 0.009 212 116 0% 0%
Lap- colpo 4875 28 0.765 −0.010 Dominated 0% 0%
10 years Retro- MUS 4905 7.270   95.0% 93.0%
Single incision sling 5271 366 7.023 −0.248 Dominated 0% 0%
Trad- sling 5471 566 7.215 −0.056 Dominated 5.0% 7.0%
Transob- MUS 5519 614 7.107 −0.163 Dominated 0% 0%
Injectable agents 5882 977 7.068 −0.202 Dominated 0% 0%
Bladder neck needle 6101 1197 7.025 −0.245 Dominated 0% 0%
Anterior repair 6629 1725 6.967 −0.303 Dominated 0% 0%
Open- colpo 7596 2691 7.204 −0.066 Dominated 0% 0%
Lap- colpo 7997 3092 7.106 −0.164 Dominated 0% 0%
Lifetime Retro- MUS 8666 24.005   51.0% 48.0%
Trad- sling 9071 405 24.014 0.009 45 340 43.0% 45.0%
Transob- MUS 10 174 1103 23.435 −0.580 Dominated 0% 0%
Single incision sling 10 189 1118 23.221 −0.793 Dominated 0% 0%
Injectable agents 10 292 1221 23.512 −0.503 Dominated 0% 0%
Bladder neck needle 10 803 1732 23.312 −0.702 Dominated 0% 0%
Open- colpo 11 605 2535 23.839 −0.175 Dominated 6.0% 7.0%
Anterior repair 11 609 2539 23.168 −0.847 Dominated 0% 0%
Lap- colpo 12 440 3369 23.522 −0.492 Dominated 0% 0%
anterior repair, anterior vaginal repair (anterior colporrhaphy); bladder neck needle, bladder neck needle suspensions; ICER, incremental cost- 
effectiveness ratio; lap- colpo, laparoscopic retropubic colposuspension; open- colpo, open abdominal retropubic colposuspension; QALY, 
quality- adjusted life- year; retro- MUS, retropubic mid- urethral sling; single incision sling, single incision sling procedures (‘mini- slings’); trad- 
sling, traditional suburethral retropubic sling procedures; transob- MUS, transobturator mid- urethral sling.
at the £20 000 and £30 000 WTP thresholds presented. 
However, over a 1- year time horizon single incision sling 
is dominant compared with all other strategies, except for 
anterior repair and open- colpo, which are both margin-
ally more effective.
Figure 2 shows that over a lifetime time horizon, both 
trad- sling and retro- MUS have a high probability of being 
cost- effective at all WTP threshold values presented. 
Given the number of comparators, if the interventions 
were comparable we would expect an 11% chance of 
each being cost- effective. The only other strategy with 
a reasonably sized probability of being cost- effective 
over the lifetime is open- colpo (6% and 7% probabili-
ties of being cost- effective at £20 000 and £30 000 WTP 
thresholds, respectively). No other strategy has a signif-
icant probability of being cost- effective at any of the 
WTP thresholds presented.
sensitivity analysis and VOI analysis
In the first sensitivity analysis (SA), results from the study 
by Keltie et al24 were used to inform the mesh complica-
tions incidence rates after retro- MUS and transob- MUS. 
Results from this SA show that retro- MUS remains the 
most cost- effective option. However, when the incidence 
rate of mesh complications following retro- MUS and tran-
sob- MUS is increased to 10%, and then 20%, trad- sling 
becomes the most cost- effective intervention (online 
supplementary table S6). Results from the second SA 
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Figure 2 Cost- effectiveness acceptability curves for the 
nine surgical treatments: lifetime time horizon. AVR, anterior 
vaginal repair; BNNS, bladder neck needle suspension; 
CE, cost- effectiveness; LRC, laparoscopic retropubic 
colposuspension; OARC, open abdominal retropubic 
colposuspension; PUI, periurethral injection; RMUS, 
retropubic mid- urethral sling; SISP, single incision sling 
procedure; TMUS, transobturator mid- urethral sling; TSRS, 
traditional sub- urethral retropubic sling.
Table 4 Results from expected value of information 
analysis
The expected value of 
removing all current 
decision uncertainty
Overall EVPI 
(£)
Overall EVPI 
(QALY)
Per person affected by the 
decision
11 857 0.56
Per year in UK assuming 
15 000 persons affected per 
year
177 855 000 8385
Over 5 years 889 275 000 41 930
Over 10 years 1 778 550 000 83 850
Over 15 years 2 667 825 000 125 800
Over 20 years 3 557 100 000 167 700
EVPI, expected value of perfect information; QALY, quality- 
adjusted life- year.
show that when a longer duration for persistent pain is 
assumed (3 and 5 years), the probability of retro- MUS 
being the most cost- effective option decreases and the 
respective probabilities for trad- sling and open- colpo 
increase. Furthermore, results from the third SA show 
that when a higher incidence rate (10% and 20%) of 
persistent pain after retro- MUS and transob- MUS is 
assumed, the probability of retro- MUS being the most 
cost- effective option decreases and the respective prob-
ability for trad- sling increases. Detailed results from all 
sensitivity analyses are reported in online supplementary 
table S6–S10, respectively.
The VOI analyses results show that the EVPI per patient 
is £11 857 and the estimated EVPI for the UK population 
for 1 year is £177.9 million. This figure increases as the 
time horizon (or period of time over which the informa-
tion would be useful) is increased (table 4). Results from 
the EVPPI analysis also show that the largest value appears 
to be in removing uncertainty around the incidence rate 
of complications and treatment effectiveness parameters. 
Results from this analysis are presented in online supple-
mentary table S11.
dIsCussIOn
To our knowledge, this economic evaluation is the most 
comprehensive assessment of the cost- effectiveness of 
surgical interventions for the treatment of SUI or stress- 
predominant MUI in women. While the broader study 
on which this paper is based9 presents the entire spec-
trum of evidence available on the clinical effectiveness, 
safety and cost- effectiveness of surgical treatments for 
SUI, the work presented here focusses specifically on the 
economic viability of these treatments. Additionally, given 
that the cost estimates included in the previous study 
are now outdated, we have considered the relative cost- 
effectiveness of alternative interventions using cost infor-
mation from the most recent price year (2019). Due to 
limited long- term clinical data, the results are uncertain 
but suggest that retro- MUS is the least costly and most 
cost- effective surgical intervention over 10- year and life-
time time horizons; results which are largely driven by the 
low initial cost of retro- MUS. This is primarily due to the 
fact that this procedure is conducted in a day- case setting, 
and there is a lower chance of needing repeat surgery due 
to its higher cure rate compared with all other surgical 
treatments (except for trad- sling). Trad- sling is the one 
alternative intervention, which has a relatively high prob-
ability of being cost- effective over 10- year and lifetime 
time horizons. This is likely driven by the high success 
rate associated with trad- sling, relative to retro- MUS. Over 
a 1- year time horizon, retro- MUS is dominated (more 
costly and less effective) by single incision sling, primarily 
due to the low initial cost of this procedure and the low 
complication rate associated with this type of surgery.
One of the strengths of our economic model is the 
evaluation of nine different surgical treatments in one 
study, informed by data from a comprehensive evidence 
synthesis and network meta- analysis where all the direct 
and indirect evidence (120 trials) were used to estimate 
the relative effectiveness of different surgical treatments 
in terms of cure rates.9 Very few cost- effectiveness studies 
in this clinical area have included complications within 
their analysis, despite the fact that the incidence of each 
complication can have an impact on the woman’s quality 
of life, and result in costs incurred for the health system. 
Therefore, in the present study the impact that compli-
cations such as infection, urge urinary incontinence, 
voiding difficulties, bladder or urethral perforation, mesh 
removal, short- term pain and persistent pain have on 
costs and effects have been incorporated into the model 
and explored in sensitivity analysis. Approximately 50% 
of women who have SUI4 also suffer from UUI symptoms; 
given that UUI potentially affects the woman’s quality of 
life more than SUI,25 treatment pathways associated with 
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UUI are also incorporated in the model to more accu-
rately estimate QALYs for this patient group. The anal-
ysis was conducted in accordance with the International 
Society of Pharmacoeconomics and Outcomes Research 
modelling guidelines26 and extensive sensitivity analyses 
were undertaken to explore and characterise uncer-
tainty in the model parameters. Our results were gener-
ally robust to the sensitivity analyses performed and are 
comparable to the findings of other published studies.
There are a number of published cost- effectiveness 
analyses evaluating some of the surgeries that we have 
assessed, the general findings of which are presented to 
allow for comparison. Two studies compared the single 
incision versus mid- urethral sling procedures over a 
1- year time horizon, concluding that single incision was 
less costly and of similar effectiveness.27 28A UK study 
compared the cost- effectiveness of retro- MUS (tension- 
free vaginal tape (TVT)) versus open colposuspension, 
laparoscopic colposuspension, trad- sling and injectable 
agents, concluding that TVT dominated open- colpo over 
a 5- year time horizon.29 A cost- utility analysis in the UK to 
assess the cost- effectiveness of TVT compared with open 
Burch colposuspension found that TVT was less costly 
and more effective.20 A further study to assess the cost- 
effectiveness of TVT versus laparoscopic mesh colposus-
pension concluded that TVT was more cost- effective over 
a 1- year time horizon.30 Although there are limitations 
with many of these studies and heterogeneity present 
in the methods, the results from all of the above studies 
are largely in agreement with the findings from our 
economic model; generally supporting the conclusion 
that retro- MUS (TVT) is likely to be the most cost- effective 
option when compared with the other types of surgeries 
for the treatment of SUI and stress- predominant MUI.
Results from the VOI analysis indicate that further 
research should focus on adverse events that, however 
rare, can have a detrimental impact on women’s quality 
of life when they do occur (eg, tape extrusion/exposure).
limitations
One of the main limitations of the current study is the 
lack of long- term data which necessitated the extrap-
olation of relatively short- term data to 10 years, and 
over the lifetime of women included in the analysis. 
Therefore, the results presented would only apply in 
a situation where relative differences in the effective-
ness of retro- MUS compared with the comparators do 
not change with longer follow- up. The long- term inci-
dence of complications after the surgical treatments are 
also currently unknown. All of the estimated incidence 
rates for complications after each surgical treatment 
were based on data from trials with relatively short- term 
follow- up times. We tested the impact of possible higher 
incidence rates of some of the complications on the 
results, to incorporate and explore some of this uncer-
tainty within our model. Finally, the economic analysis 
included costs to the NHS only. As highlighted earlier, 
individual patients also buy different products and incur 
the costs of containment products themselves; a future 
analysis may also need to consider these out- of- pocket 
costs to patients.
COnClusIOns
The results of this study suggest that, in the medium- term 
and long- term, retro- MUS is less costly and more effec-
tive than all other surgical interventions for the treatment 
of SUI; therefore, it is a dominant strategy. However, the 
results should be interpreted with caution as the long- 
term performance of all surgical treatments in terms 
of both continence and unanticipated adverse effects is 
not reliably known. Therefore, the results presented are 
based on the extrapolation of short- term and medium- 
term evidence.
Author affiliations
1Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
UK
2Health Services Research Unit, University of Aberdeen, Aberdeen, UK
3Academic Urology Unit/Cochrane Incontinence Group, University of Aberdeen, 
Aberdeen, UK
4Gynaecology, University Hospitals Southampton Foundation Trust, Southampton, UK
5Obstetrics and Gynaecology, Aberdeen Royal Infirmary, Aberdeen, UK
6Scottish Public Health Network, NHS Health Scotland, Glasgow, UK
7Health Economics Research Centre, University of Oxford, Oxford, UK
twitter Eoin Moloney @eoin_moloney1 and Muhammad Imran Omar @
drimranomar
Acknowledgements We would like to acknowledge all those involved in the wider 
study exploring the effectiveness and cost- effectiveness of surgical treatments for 
women with stress urinary incontinence.
Contributors MJ, DC, EM, LT and LV designed the study. MJ and EM built the 
model and ran the analyses. DC, MB, LS, PM, JH, GM and LV helped to inform 
the model. All co- authors (EM, MB, SW, LT, MIO, AM, LS, PM, FB, MI, JH, MS, GM, 
LV, DC) commented on the draft version of the manuscript and approved its final 
version.
Funding This research was commissioned by the NIHR HTA Programme as 
project number 15/09/06. The views expressed are those of the authors and not 
necessarily those of the NHS, the NIHR or the Department of Health and Social 
Care, UK. The funders were not actively involved in the research process at any 
stage. The study design, collection, analysis and interpretation of data, the writing 
of the manuscript and the decision to submit it for publication were all performed 
independent of the funders.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCId ids
Mehdi Javanbakht http:// orcid. org/ 0000- 0002- 8661- 8439
Eoin Moloney http:// orcid. org/ 0000- 0002- 3025- 5413
Miriam Brazzelli http:// orcid. org/ 0000- 0002- 7576- 6751
Jemma Hudson http:// orcid. org/ 0000- 0002- 6440- 6419
Graeme MacLennan http:// orcid. org/ 0000- 0002- 1039- 5646
 o
n
 June 12, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035555 on 11 June 2020. Downloaded from 
8 Javanbakht M, et al. BMJ Open 2020;10:e035555. doi:10.1136/bmjopen-2019-035555
Open access 
reFerenCes
 1 Kwon BE, Kim GY, Son YJ, et al. Quality of life of women with 
urinary incontinence: a systematic literature review. Int Neurourol J 
2010;14:133–8.
 2 Papanicolaou S, Pons ME, Hampel C, et al. Medical resource 
utilisation and cost of care for women seeking treatment for urinary 
incontinence in an outpatient setting. examples from three countries 
participating in the pure study. Maturitas 2005;52 Suppl 2:S35–47.
 3 Hannestad YS, Rortveit G, Sandvik H, et al. A community- based 
epidemiological survey of female urinary incontinence: the 
Norwegian EPINCONT study. epidemiology of incontinence in the 
County of Nord- Trøndelag. J Clin Epidemiol 2000;53:1150–7.
 4 Hunskaar S, Lose G, Sykes D, et al. The prevalence of urinary 
incontinence in women in four European countries. BJU Int 
2004;93:324–30.
 5 Turner DA, Shaw C, McGrother CW, et al. The cost of clinically 
significant urinary storage symptoms for community dwelling adults 
in the UK. BJU Int 2004;93:1246–52.
 6 Urinary incontinence in women. The management of urinary 
incontinence in women CG171: National Institute for health and 
care excellence, 2013. Available: https://www. nice. org. uk/ guidance/ 
cg171/ evidence/ urinary- incontinence- in- women- full- guideline- 
191581165
 7 Sung VW, Schleinitz MD, Rardin CR, et al. Comparison of retropubic 
vs transobturator approach to midurethral slings: a systematic review 
and meta- analysis. Am J Obstet Gynecol 2007;197:3–11.
 8 Chuang K- W. Surgical Management of Stress Urinary Incontinence. 
In: Firoozi F, ed. Female pelvic surgery. New York, NY: Springer New 
York, 2015: 39–54.
 9 Brazzelli M, Javanbakht M, Imamura M, et al. The effectiveness and 
cost- effectiveness of surgical treatments for womEn with stRess 
urinary incontinence: an evidence synthesis economic evaluation and 
discrete choice experiment. Health Technol Assess
 10 Morling J, Wood R. Using routinely available health data to examine 
the provision of, and outcomes following, surgery for SUI and POP 
in Scotland: technical report information services division, NHS 
national services Scotland, 2015. Available: http://www. gov. scot/ 
Publications/ 2015/ 10/ 8485/ downloads.
 11 Excellence NIfHaC. Guide to the methods of technology appraisal 
2013, 2013. Available: https://www. nice. org. uk/ process/ pmg9/ 
resources/ guide- to- the- methods- of- technology- appraisal- 2013- pdf- 
2007975843781
 12 TreeAge Pro. TreeAge Software, Williamstown, MA, 2017. Available: 
https://www. treeage. com
 13 Cody J, Wyness L, Wallace S, et al. Systematic review of the clinical 
effectiveness and cost- effectiveness of tension- free vaginal tape 
for treatment of urinary stress incontinence. Health Technol Assess 
2003;7:1–189.
 14 Lunn DJ, Thomas A, Best N, et al. WinBUGS- a Bayesian modelling 
framework: concepts, structure, and extensibility. Stat Comput 
2000;10:325–37.
 15 Zilberman D, Kaplan S, Wesseler J. The loss from underutilizing GM 
technologies. AgBio Forum 2015;18:312–9.
 16 Imamura M, Abrams P, Bain C, et al. Systematic review and 
economic modelling of the effectiveness and cost- effectiveness of 
non- surgical treatments for women with stress urinary incontinence. 
Health Technol Assess 2010;14:1–188.
 17 Health Do. Reference costs 2017-18, 2018. Available: https:// 
improvement. nhs. uk/ resources/ reference- costs/
 18 Curtis L, Burns A. Unit Costs of Health & Social Care 2016. The 
University of Kent, 2016.
 19 British National Formulary. BNF online. Available: https://www. 
medicinescomplete. com/ mc/? utm_ source= bnforg& utm_ medium= 
homepage& utm_ campaign= medicinescomplete
 20 Manca A, Sculpher MJ, Ward K, et al. A cost- utility analysis of 
tension- free vaginal tape versus colposuspension for primary 
urodynamic stress incontinence. BJOG 2003;110:255–62.
 21 Haywood KL, Garratt AM, Lall R, et al. EuroQol EQ- 5D and 
condition- specific measures of health outcome in women with 
urinary incontinence: reliability, validity and responsiveness. Qual Life 
Res 2008;17:475–83.
 22 Kunkle CM, Hallock JL, Hu X, et al. Cost utility analysis of 
urethral bulking agents versus midurethral sling in stress urinary 
incontinence. Female Pelvic Med Reconstr Surg 2015;21:154–9.
 23 Shepherd JP, Lowder JL, Jones KA, et al. Retropubic and 
transobturator midurethral slings: a decision analysis to compare 
outcomes including efficacy and complications. Int Urogynecol J 
2010;21:787–93.
 24 Keltie K, Elneil S, Monga A, et al. Complications following vaginal 
mesh procedures for stress urinary incontinence: an 8 year study of 
92,246 women. Sci Rep 2017;7:12015.
 25 Tincello D, Sculpher M, Tunn R, et al. Patient characteristics 
impacting health state index scores, measured by the EQ- 5D of 
females with stress urinary incontinence symptoms. Value Health 
2010;13:112–8.
 26 Caro JJ, Briggs AH, Siebert U, et al. Modeling good research 
practices--overview: a report of the ISPOR- SMDM Modeling Good 
Research Practices Task Force--1. Value Health 2012;15:796–803.
 27 Costantini E, Lazzeri M, Bini V, et al. Managing female urinary 
incontinence: a regional prospective analysis of cost- utility ratios 
(curs) and effectiveness. Arch Ital Urol Androl 2014;86:112–7.
 28 Boyers D, Kilonzo M, Mostafa A, et al. Comparison of an adjustable 
anchored single- incision mini- sling, Ajust(®), with a standard mid- 
urethral sling, TVT- O(TM) : a health economic evaluation. BJU Int 
2013;112:1169–77.
 29 Kilonzo M, Vale L, Stearns SC, et al. Cost effectiveness of tension- 
free vaginal tape for the surgical management of female stress 
incontinence. Int J Technol Assess Health Care 2004;20:455–63.
 30 Valpas A, Rissanen P, Kujansuu E, et al. A cost- effectiveness 
analysis of tension- free vaginal tape versus laparoscopic mesh 
colposuspension for primary female stress incontinence. Acta Obstet 
Gynecol Scand 2006;85:1485–90.
 o
n
 June 12, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035555 on 11 June 2020. Downloaded from 
